Longer colonoscopy withdrawal times associated with lower cancer rate
the ONA take:
Colonoscopy withdrawal times of 6 minutes or more are associated with lower colon cancer rates, according to research by a Veterans Affairs team.
The link between colonoscopy withdrawal time and patient outcomes is already known; this study provides strong evidence to support clinical guidelines regarding colonoscopy withdrawal times. Current guidelines recommend a withdrawal time of 6 minutes or more.
In this study, data on colonoscopies performed over 6 years by 51 gastroenterologists in a large community practice were evaluated. The average withdrawal time for the practice was 8.6 minutes; however, approximately 10% of the doctors had individual averages of less than 6 minutes.
The researchers then reviewed the state’s cancer registry for colorectal cancer cases among patients who had been screened at the practice during the study period, including cancers that occurred within 5 years of the last screening.
Referred to as interval cancers, these cancers are assumed to have developed from polyps that were either not detected during the colonoscopy, or not fully removed.
The American College of Gastroenterology acknowledges that some colons can be effectively examined in less than 6 minutes, but these findings show longer colonoscopy withdrawal times correlate with lower risk for interval cancer. The researchers report that further research is needed on quality measures for this screening procedure.
Colonoscopy withdrawal times of 6 minutes or more are associated with lower colon cancer rates.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|